{"disease":{"id":"double-expressor-dlbcl","name":"double expressor dlbcl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07415980","title":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06736613","title":"A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}